Josephine Harada was recently appointed Vice President of Business Development at Thrive Earlier Detection, following its $100M Series A. Thrive is a healthcare company focused on incorporating earlier cancer detection into routine medical care to extend and save lives. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. Thrive closed a $257M Series B in July 2020 to support its registration studies and commercialization efforts.
Prior to Thrive, Josephine served as the Head of Business Development at 10x Genomics, where she oversaw all business development activities and implemented and managed strategic partnerships to accelerate and strengthen 10x Genomics’ platform and application pipeline. Previously, she additionally executed strategic partnerships with biopharmaceutical companies as part of the business development team at Foundation Medicine, a company dedicated to transforming cancer care by delivering molecular insights on each patient’s unique cancer to inform the selection of targeted and immunotherapies.
Josephine started her scientific career at the Genomics Institute of the Novartis Research Foundation and the Scripps Research Institute developing advanced genomic technologies. Dr. Harada completed her PhD in Molecular Biology at UCLA, received her MBA with a focus on Healthcare Management and Finance from the Wharton School, and holds a BS from MIT in Biology. A passionate advocate of genomic medicine, Josephine remains committed to the development of genomic innovator products and molecular therapies and to accelerating the adoption of personalized medicine interventions into mainstream care.
Contact Josephine at: